01/06/2016 - 1:53pm

The bill would grant pharmacists the legal protection to decline potentially illegitimate sales of PSE products that lack meth-resistant features where appropriate.

01/06/2016 - 12:10pm

According to statistics compiled by the National Institute on Deafness and Other Communication Disorders, 37.5 million adults aged 18 and older in America report some form of hearing loss. 

01/04/2016 - 11:40am

In the 20 years since the establishment of the dietary supplement program, the dietary supplement industry has grown from about $6 billion to more than $35 billion in annual sales, FDA reported. 

01/04/2016 - 11:25am

Forbes on Monday reported the formation of a coalition known as "The Patient Access to Pharmacists' Care Coalition," which is advocating Medicare reimbursement for senior immunizations. "Our immunization program continues to demonstrate the important role our 27,000 pharmacists are playing in healthcare delivery today, providing greater access than ever before to a wide range of CDC-recommended vaccines, as well as other important, preventive healthcare services," Walgreens said in a statement. (Forbes

01/04/2016 - 11:09am
A total of 24 Republicans and 20 Democrats, including a total of 11 members of the House Energy and Commerce Committee, shared their support of retail pharmacy as qualified MTM providers. 
12/30/2015 - 11:32am

Lupin in late December received U.S. Food and Drug Administration approval for its Fyavolv (norethindrone acetate and ethinyl estradiol) tablets, the generic version of Warner Chilcott's Femhrt tablets.

12/28/2015 - 4:37pm

Food and Drug Administration approved the company's famotidine tablets to treat gastroesophageal reflux diesease and active duodenal ulcer.

12/23/2015 - 3:01pm

The Food and Drug Administration on Tuesday announced that it approved AstraZeneca's Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when combined with a xanthine oxidase inhibitor.

12/23/2015 - 1:37pm

The Food and Drug Administration on Monday approved Actelion Pharmaceutivals' Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension.